SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) By Dr Rose Hughes on Friday, June 28, 2019 article 3(c) biologics canakinumab CJEU Ilaris monocolonal antibody Novartis patents pharmaceutical industry Second medical use SPC SPC regulation Supplementary Protection Certificate +